Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD

What is it about?

Sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP1-RA) slow the worsening of kidney disease and improve cardiovascular outcomes in patients with chronic kidney disease. We showed that among patients with chronic kidney disease, these agents are frequently discontinued, and discontinuation is associated with hospitalization, race, ethnicity, and vascular disease. Discontinuation of these agents is also associated with harmful outcomes including death.

Featured Image